# Study of AGEN1884 With Pembrolizumab in 1L NSCLC

> **NCT03411473** · PHASE2 · TERMINATED · sponsor: **Agenus Inc.** · enrollment: 2 (actual)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **BIOLOGICAL:** AGEN1884 in combination with pembrolizumab

## Key facts

- **NCT ID:** NCT03411473
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-04
- **Primary completion:** 2018-05-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Trial will not proceed due to changes in the treatment landscape.
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03411473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03411473, "Study of AGEN1884 With Pembrolizumab in 1L NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03411473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*